19 March 2026

Clinical Obesity Pregnancy

It’s not just mum’s BMI that impacts a child’s risk of MASLD

15 January 2026

Obesity Osteoarthritis Pain Pharmaceuticals

There’s a new weight loss drug in town

13 January 2026

Obesity Public Health

Stopping weight-loss drugs triggers rapid rebound

3 December 2025

Guidelines Obesity Pharmaceuticals

WHO backs GLP-1s for obesity, but can Australia deliver?

2 December 2025

Clinical Obesity

Bruxism and temporomandibular disorders in GP

24 November 2025

Clinical Obesity Sleep

GLP-1s for sleep apnoea – are they a game-changer?

24 November 2025

Obesity Pharmaceuticals Surgery

GLP-1s could help avoid follow-up bariatric surgery

4 November 2025

Diabetes Obesity Pharmaceuticals

UK regulators smash illegal weight-loss drug factory

16 October 2025

Diabetes Obesity

GLP-1 RAs linked to rising rates of hair loss

14 October 2025

Obesity Pharmaceuticals

If not BMI for GLP-1s, then what?

10 October 2025

Clinical Obesity

Tirzepatide vs semaglutide: A head-to-head comparison

25 September 2025

Obesity PBS Pharmaceuticals

Equity now the missing link for GLP-1s

24 September 2025

Clinical research Obesity

BMJ retracts vinegar weight loss trial

22 September 2025

Diabetes Obesity Pharmaceuticals

Higher dose GLP1-RA enhances weight and metabolic outcomes: trial

10 September 2025

Clinical Obesity Weight management

Obesity as a chronic disease: Rethinking assessment and escalation of care

28 August 2025

Cancer Obesity Pharmaceuticals

GLP-1 drugs linked to lower cancer risk in obese people